- 期刊
Gefitinib Treatment for Non-Small Cell Lung Cancer-A Study Including Patients with Poor Performance Status
Gefitinib在非小細胞肺癌病人中的治療經驗－一個有納入活動能力較差的病患之研究
並列摘要
Background and Purpose: Gefitinib is effective in the treatment of advanced non small tell lung cancer (NSCLC) However, most studies have only investigated patients who have good performance status or are, evaluable. This study evaluated the efficacy of gefitinib in a consecutive series of patients with NSCLC. Methods: The treatment response of all gefitinib-trated NSCLC patients from November 2001 to September 2003 at a single medical institute was retrospectively evaluated All patients receiving at least 1 dose of gefitinib during the study period were included. Results: A total of 66 NSCLC patients were treated including 22 patients with Eastern Clinical Oncology Group performance status 3 or 4 No prior chemotherapy had been given in 14 patients because of their personal preference or poor general condition The duration of treatment ranged from 1 day to 19.3 months (median 2.5 months) The partial remission rate was 15.2% and the stable disease rate was 25.8%. The median survival for all patients was 5.9 months and the 1 year survival rate was 27.9% Symptom improvement and response correlated well to survival Female gender non smoking status and performance status of 0-2 were associated with better survival The disease control rate was 22.7% in patients with performance Status of 3-4. Conclusions: Gefitinib can be recommended for the treatment of advanced NSCLC in patients for whom standard chemotherapy is not an option. Further study is required to determin the optimal selection criteria of patients and the timing of starting therapy.
被引用紀錄
延伸閱讀
- 黃詩涵（2018）。Semaphorin 6A在非小細胞肺癌細胞株中所造成的免疫刺激效果及機制之研究〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU201704447
- Chen, K. C., Chang, G. C., Yang, T. T., Kuo, B. I. T., Lin, C. P., & Hsu, J. Y. (2004). 比較Gefitinib與Cisplatin和Gemcitabine合併治療用於未經治療的晚期非小細胞肺癌之差異－病例對照研究. 胸腔醫學, 19(5), 340-345. https://doi.org/10.29806/TM.200410.0004
- 王智亮、王美嘉、張仕政、劉秀玲、張璧月（2021）。探討非小細胞肺癌病人循環腫瘤DNA基因圖譜及其與標靶治療反應之關係。Journal of Biomedical & Laboratory Sciences，33(3)，143-152。https://www.airitilibrary.com/Article/Detail?DocID=10137653-202109-202109300012-202109300012-143-152
- 張基晟、陳焜結、楊宗穎、林聖皓、徐國軒（2008）。年齡增加在非小細胞肺癌使用Gefitinib治療是個預測因子。中華民國癌症醫學會雜誌，24(6)，362-371。https://doi.org/10.6588/JCOS.2008.24.6.4
- Yang, C. T., Hung, J. Y., Lai, C. L., Hung, H. C., Lai, Y. F., Lin, M. C., Shieh, J. M., & Huang, M. S. (2010). 以Gefitinib為第一線藥物治療南台灣晚期非小細胞肺癌病患之經驗. The Kaohsiung Journal of Medical Sciences, 26(1), 1-7. https://www.airitilibrary.com/Article/Detail?DocID=1607551X-201001-201003030044-201003030044-1-7